Lotta E. Oikari

This study identifies proteomic and transcriptomic changes in olfactory stem cells from AD and MCI patients, revealing pathway-level overlaps and potential biomarkers.

The paper uses computational drug repurposing to identify N-acetylglucosamine as a potential therapy for CLN3 Batten disease, showing it reduces lipofuscin burden in cell models.

This paper develops a patient-derived BBB model to screen copper bis(thiosemicarbazone) complexes for Alzheimer's disease treatment, identifying CuII(dtsm) as a promising candidate with improved BBB permeability and anti-inflammatory effects.

This study develops a human ALS patient-derived BBB model to show focused ultrasound with microbubbles enhances anti-TDP-43 antibody delivery across the BBB in vitro.

This study shows that APOE4 increases tau levels in brain endothelial cells, reducing anti-tau antibody delivery across the blood-brain barrier in vitro.

The paper uses olfactory cells from Alzheimer's patients to identify gene expression changes linked to cognitive decline.

This paper develops a method to generate monocyte-derived microglia from ALS patient blood, revealing functional impairments and pathological features associated with disease progression.

This study demonstrates that focused ultrasound with microbubbles enhances the delivery of Aducanumab and anti-Tau antibodies across a human sporadic Alzheimer's disease blood-brain barrier model.

This study develops 3D models of Alzheimer's patient microglia that show distinct disease features and drug responses compared to 2D cultures.